Femasys' first revenue-generating FemaSeed Complete use inside an OB/GYN office is a small commercial event with a larger institutional insult embedded in it.

The fertility industry has been allowed to concentrate around referral funnels, specialist clinics, lab choreography, and the psychological cliff of IVF. That structure is clinically serious, but it also turns early infertility care into a gated maze. FemaSeed and FemSperm try to move the first intervention back into the room where women already are, with in-office sperm prep and intratubal insemination treated as a routine workflow rather than a pilgrimage.

The hard part is execution, reimbursement, physician training, patient selection, and proof that outcomes survive outside specialist centers. Fine. Those are the right problems. A market that can push reproductive care down the complexity curve is doing something more civilized than another benefits-platform sermon about access.